GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (NAS:NYXH) » Definitions » COGS-to-Revenue

Nyxoah (Nyxoah) COGS-to-Revenue : 0.37 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah COGS-to-Revenue?

Nyxoah's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.49 Mil. Its Revenue for the three months ended in Mar. 2024 was $1.33 Mil.

Nyxoah's COGS to Revenue for the three months ended in Mar. 2024 was 0.37.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nyxoah's Gross Margin % for the three months ended in Mar. 2024 was 62.77%.


Nyxoah COGS-to-Revenue Historical Data

The historical data trend for Nyxoah's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah COGS-to-Revenue Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - 0.44 0.36 0.37 0.38

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.38 0.34 0.40 0.37

Nyxoah COGS-to-Revenue Calculation

Nyxoah's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.806 / 4.742
=0.38

Nyxoah's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.494 / 1.327
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyxoah  (NAS:NYXH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Nyxoah's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.494 / 1.327
=62.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Nyxoah COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nyxoah's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyxoah (Nyxoah) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.